The invention relates to novel keto lactam compounds, hydrogenated derivativesand tautomers thereof. These compounds have valuable therapeutic propertiesand are particularly suited for treating diseases that respond to themodulation of the dopamine D3 receptor. The keto lactams have general formula(I), wherein: (a) represents a group of formulas (b) or (c), wherein D isbound to the nitrogen atom and W, Rp and Rq have the meanings cited in Claim1； -B- represents a bond or (d), wherein Rm and Rn have the meanings cited inClaim 1； (e) represents a single bond or a double bond； Rv, Rw, Rx and Ry havethe meanings cited in Claim 1； D represents a linear or branched 2 to 10-membered alkylene chain that can have, as chain members, a heteroatom group K,which is selected among O, S, S(O), S(O)2, N-R8, CO-O, C(O)NR8 and/or 1 or 2non-adjacent carbonyl groups and which can have a cycloalkane diyl groupand/or a double or triple bond； (f) represents a saturated or monounsaturatedmonocyclic nitrogen heterocyclic compound having 5 to 8 cyclic members or abicyclic saturated nitrogen heterocyclic compound having 7 to 12 cyclicmembers.
